Introduction
When determining likely prognostic advantage for interventional management, that is invasive angiography with or without subsequent revascularization based on coronary angiography findings, the determination of patient risk and estimation of likely benefit is heterogeneous and subjective. Previous studies have suggested that clinical care is risk averse and therefore misdirected with routine invasive management being offered more frequently to patients of lower risk, when compared with patients with very high risk. 1 -5 Over the last 17 years, the acute coronary syndrome (ACS) evidence base regarding the routine early invasive strategy has consolidated and as a consequence Australian management of ACS patients has evolved. In response to the publication of the first Heart Foundation and Cardiac Society of Australia and New Zealand (HF/ CSANZ) guideline for the management of ACS, 6 and with the ongoing publication of studies supporting an early invasive approach, the proportion of patients receiving invasive management vs. those conservatively managed has increased. 7 This change in practice presents the opportunity to explore if the more liberal provision of invasive management has been both risk-appropriate and associated with improvements in mortality. Conversely, among patients in whom medical management has been deemed appropriate, short-and longterm event-free survival has been shown to be poorer and, in addition to this, the consequences of the change in practice over time on those managed conservatively is also poorly documented. 8 This pooled analysis of all the ACS registries conducted in Australia aims to: document the change in the use of angiography for the management of ACS across the region; examine the evolution in patient selection and practice by specific objectively defined risk characteristics; and explore whether this change in practice is associated with any temporal change in mortality for invasively and conservatively managed patients.
Method Study design and studies included
This study is a pooled analysis of Australian registries pertaining to ACS patient admissions over the last 17 years ( Figure 1 ). These registries have been published elsewhere with major applications in observing and monitoring guideline appropriate treatment, risk assessment, and clinical outcomes in ACS patients. Descriptive characteristics and median duration of follow-up for each of the studies are provided in Table 1 . In brief, the Global Registry of Acute Coronary Events (GRACE) was a multi-national registry conducted from April 1999 to 2007, and included 95 hospitals across 14 countries in Europe, North and South America, Australia and New Zealand, and provided insight into differences in management outcomes based on geographical location. 9 The
Australian Acute Coronary Syndromes Prospective Audit (ACACIA) was conducted over 1 November 2005 -31 July 2007 and observed clinical outcomes in practice at 39 hospitals in Australia. 10 The Cooperative National Registry of Acute Coronary care, Guideline Adherence and Clinical Events (CONCORDANCE) provided insight into clinical care in ACS patients across 20 regional and metropolitan hospitals in Australia between 2009 and 2015. 11 The Snapshot-ACS study examined evidence-based practice in 286 hospitals in Australia and New Zealand over a 2-wk period in May 2012. 12 The Predict study was a multinational registry conducted over 58 hospitals in China, Russia, India, and Australia, and evaluated risk appropriation among ACS patients between May 2009 and February 2011. Only patients enrolled within Australia were retained for analysis from each registry. Patients were included into the study if they were discharged from hospital with a diagnosis of an ACS; that is, unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). Trained clinical trial staff collected all of the data. Informed consent was obtained from each patient through the original registries.
1,9 -12 Patient confidentiality was maintained, no attempt was made to contact patients. The study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the appropriate human research committee.
Patients and data collection
Data pertaining to patient demographic, management and clinical outcomes during the index admission were extracted. Patient risk characteristics, specifically age (,55 years, 55 -74 years, and ≥75 years), type of ACS at the time of discharge (UA, NSTEMI, STEMI), the presence of electrocardiogram (ECG) changes and/or biomarker elevation, and GRACE score were assessed. For each study, the components of the GRACE score reported for each patient were extracted and collated using the scoring system reported by Fox et al. (BMJ 2006) . Patients with missing variables required for generation of the GRACE risk score, allocation to diagnostic group or year of enrolment were excluded. Consistent with the primary analyses from these cohorts, missing baseline co-morbidities were considered not to have been present at the time of enrolment and set to null. Management type during the indexed admission was defined as management without an angiogram, with invasive angiography only (defined as patients who underwent an angiogram without revascularization followed by medical management at any time during the index hospitalization), or those who had angiography and revascularization [percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)]. For patients with STEMI, invasive management included those undergoing angiography and PCI as primary reperfusion. The use of various medications at discharge, including aspirin, b-blockers, angiotensinconverting enzyme (ACE) inhibitors/angiotensin-receptor blocker (ARB), statins, and P2Y12 receptor inhibitors, was obtained.
Clinical outcomes were defined as all-cause mortality and new or recurrent myocardial infarction (MI) and new reported as major adverse cardiac events (MACE) occurring following initial presentation up to 6 months. Definitions for the non-fatal events relied on the criteria and event identification/reporting methods employed in the primary studies.
Statistical methods
To assess the temporal change in patient cohorts, clinical practice and outcomes, the patient-level data are stratified into three time intervals over the 17-year period; 1999 -2004, 2005 -2009, and 2010 -2015 . Continuous variables are expressed as medians (with an interquartile range) while categorical baseline and outcome variables are presented as counts (%). Comparisons of these variables across the three time intervals were examined using Kruskal -Wallis tests for continuous variables, and x 2 tests for categorical variables. Nelson -Aalen curves present the cumulative hazard for patients managed medically, those undergoing angiography only, and among those receiving some form of revascularization within the entire cohort. Crude mortality rates are described throughout. However, to explore the temporal change in risk among patients not undergoing invasive management, hazard ratios (with a 95% confidence interval) associated with conservative management were estimated using a Cox proportional hazards model adjusting for GRACE score as a continuous variable. This model was stratified by discharge diagnosis given the differing survival curves associated with the different ACS diagnoses (i.e. STEMI, NSTEMI, and UA), and clustered on study to adjust for correlation in outcomes within enrolling registry. Within this model, the interactions between conservative management and the three temporal cohorts were explored as indicator variables (i. 13 Since the cohort definitions, invasive management, the discharge therapies, and deaths by 6 months are dichotomous variables, all of these analyses used logistic regression models. In this approach, an association between the temporal cohort (2005 -2009 and 2010 -2015 vs. 1999 -2004 ) and 6-month mortality, an association between the temporal cohort and the use of invasive management and an association between invasive management and 6-month mortality was established. Hence, the total effect (i.e. explained by changes in patient characteristics, changes in therapies, and changes in invasive management) of the time interval is captured by the coefficient within the model without the inclusion of angiography and revascularization, while the proportional of this coefficient explained by the inclusion of angiography and revascularization in the model defines the indirect effect (i.e. that explained by invasive management). Furthermore, since multiple mediators can be modelled simultaneously, discharge medications were included, but have not been reported due to modest and nonsignificant effects at the 6-month time point. Each of these models adjusts for differences in age, the GRACE risk score, diabetes, enrolling study and renal function by estimated glomerular filtration rate (eGFR) grouping (.90, 60-90, 30-59, and ,30 mL/min), and deaths occurring within the first 24 h of admission are excluded. To estimate the degree of mediation by patient risk, these models are confined to low-, intermediate-, and high-risk groups using the GRACE score categories. Bootstrap methods (500 iterations) are used to estimate the confidence intervals. STATA 14 (College Station, TX, USA) software is used to analyse data and a P-value of ,0.05 was considered statistically significant.
Results
A total of 21 846 patients were available for analysis across the five registries. After excluding those patients without a final diagnosis of 
Clinical outcomes stratified by type of invasive management
Mortality by invasive management in ACS patients for the entire cohort is shown in Figure 2 . Six-month all-cause mortality rates were 
Change in clinical practice correlated by risk characterization
The temporal change in the provision of invasive management based on risk criteria, i.e. age, ACS diagnostic group, cardiac biomarker elevation and ECG changes, and GRACE score are displayed (Supplementary material online, Appendix Figures S1 and S2 and Appendix Table S1 ). In all risk categories, the use of invasive management over time and associated 6-month mortality improved over time ( Figure 3) . Using mediation analysis, the provision of invasive management overall appeared to explain 15% (95% CI 4 -26%) and 35% (95% CI Note: n/a indicates data that was not collected. GRACE, Global Registry of Acute Coronary Events; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; AF, atrial fibrillation; LV, left ventricular; ACS, acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; UA, unstable angina; MACE, major adverse cardiac event. 
Discussion
This study spans across a 17-year period and provides large-scale observational data on the management of ACS patients in Australia. It commenced when initial trials supporting invasive management in ACS were published. 14 -16 Rather than seeking to adjust for the clinical selection-biases that are inherent and often appropriate in clinical practice, we have explored the impact of the temporal change in practice contrasted with patient risk characteristics and its correlation with changes in outcome over time. We report that (i) the rate of use of interventional management has increased over time;
(ii) interventional management and, in particular, revascularization has increased in higher risk patients; (iii) better outcomes were seen in higher risk patients who underwent invasive management; and (iv) those patients treated with medical management-only have worse outcomes even after risk adjustment.
While clinical registries and observational study designs do not replace randomized clinical trials in determining treatment efficacy, these studies provide important insights into the actual clinical outcomes of patients which are more representative of the overall community population. 17 The observation that patients undergoing angiography without revascularization have improved outcomes compared with those managed conservatively highlights the powerful impact of patient selection on interpreting treatment efficacy. Nonetheless, registries document changes in clinical practice and while patient-specific use of invasive management is at the core of ACS practice, the temporal change in this practice offers the opportunity to explore the impact of such changes on outcomes. 18 With the increasing implementation of invasive management, improvements in outcome are seen over time, lending support to the existing evidence base. 19, 20 Even though these findings are reassuring and support a more aggressive approach in the management of ACS, the value from a routine invasive strategy remains dependent on the patient's baseline risk. 21 Across this large-scale study our results indicate a temporal association between increased invasive management and decreased 6-month mortality in high-risk patient groups by the various risk criteria. Nonetheless, a substantial increase in the use of routine invasive management was also evident among patients within the lower risk strata by various criteria. Extending routine angiography to these patients was associated with modest changes in outcome and suggests potential overuse of invasive management among lower risk patients emphasizing that appropriate risk stratification represents an important aspect of achieving clinical effectiveness in ACS care. Notably, this study also highlights that ACS patients treated with medical management alone had worse outcomes now compared with the earlier registry data, which has been shown previously 22 (reviewer reference). This is most likely due to an enrichment of the population with very high-risk patients managed medically (for undetermined reasons), resulting from a greater clinical willingness to undertake invasive management in moderate-to high-risk patients. In addition, the observation that these medically managed very high-risk patients also receive less complete guideline-advocated pharmacotherapies, suggests selective prescription of therapies based on patient co-morbidities. 10 Nevertheless, a greater emphasis on improving the use of guideline-recommended evidence-based management strategies across the entire ACS spectrum base is now the focus of national policy efforts. 23 
Study limitations
Several limitations should be considered. First, as with all temporal analyses, secular changes in the background risk of the population may also explain the differences in clinical outcomes over time. However, the lack of difference in the median GRACE score within each of the three time intervals would suggest that changes in the baseline risk profile do not completely explain the differences in outcome. Furthermore, these conclusions are supported by the mediation analysis which is designed to address such confounding. Second, the identification of the diagnostic groups and the risk criteria are based on site reports and were not independently adjudicated. Nevertheless, assuming no systematic bias in diagnosis and risk reporting, misclassification at random reduces the power to detect differences between groups, but does not nullify the findings if differences are observed. Finally, while registries report patient outcomes that are more representative, due to differences in sampling strategies, some of these (excluding SNAPSHOT ACS) were somewhat selective, and this may have unappreciated differences with the entire patient population experiencing ACS. Indeed, this was observed in the different practice and outcome evident in SNAPSHOT ACS when compared with the earlier registries. 24 We have attempted to account for this with the use of clustering by study within the analytic approach.
Conclusions
Our study emphasizes the increased use of invasive management in higher risk ACS patients and better 6-month mortality associated with invasive management among high-risk patients. It also highlights the need for ongoing policy and health service interventions that focus on the optimization of invasive and non-invasive care and outcomes associated with medical care in ACS groups.
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